Antiglaucoma Medications during Pregnancy and the Risk of Low Birthweight: A Population-based Study
- Jau-Der Ho,
- Chao-Chien Hu,
- Herng-Ching Lin (henry11111{at}tmu.edu.tw)
- Department of Ophthalmology, Taipei Medical University Hospital, Taiwan
- Department of Ophthalmology, Shin Kong Wu-HoSu Memorial Hospital, Taiwan
- Taipei Medical University, Taiwan
- Published Online First 10 June 2009
Abstract
Objective: To study the relationship between using antiglaucoma medications during pregnancy and the risk of having low birthweight (LBW) infants.
Methods: The study group comprised 244 pregnant women who had been prescribed topical medication to control glaucoma during pregnancy. The comparison group comprised 1,952 pregnant women matched for age, year of delivery, maternal hypertension and gestational diabetes. Multivariate logistic regressions were conducted to calculate the adjusted odds ratio of having LBW infants.
Results: The majority of pregnant women (77.5%) were prescribed beta-blockers to control glaucoma. After adjusting for characteristics of the infant (gender, parity, and gestational age), mother (age, the highest educational level, marital status, hypertension, and gestational diabetes), father (the highest educational level), parental age difference and family monthly income, there was no significant difference in the risk of LBW infants between mothers prescribed beta-blockers and mothers in the comparison cohort (adjusted odds ratio [OR] = 1.48, 95% confidence interval [C.I.] = 0.86-2.56). However, there was a significantly higher risk of LBW infants for mothers prescribed topical antiglaucoma medications other than beta-blockers (adjusted OR = 2.15, 95% C.I. = 1.05-5.00).
Conclusions: Topical beta-blockers can be the first-line drugs when considering medical treatment of glaucoma in a pregnant woman.
